Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mailuoning Granules versus Dengzhanshengmai Capsule for convalescent cerebral infarction
ChiCTR2200066729Phase 4Not yet recruiting
- Sponsor
- Jiangxi Provincial People's Hospital
- Start
- Jul 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Mailuoning in brain infarction and ischemic stroke (2 arms), sponsored by Jiangxi Provincial People's Hospital. Primary endpoints: NIHSS score, modified Rankin Scale score and 1 more. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
Mailuoning
03
Conditions
brain infarctionischemic stroke
Beyond the preview
Go deeper on ChiCTR2200066729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066729.